Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 13 results
[
Author
]
Title
Type
Year
Filters:
Keyword
is
Treatment Outcome
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
B
Battat R
,
Kopylov U
,
Bessissow T
,
Bitton A
,
Cohen A
,
Jain A
,
Martel M
,
Seidman E
,
Afif W
. 2017.
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
.
Clin Gastroenterol Hepatol. 15(9):1427-1434.e2.
Battat R
,
Hemperly A
,
Truong S
,
Whitmire N
,
Boland BS
,
Dulai PS
,
Holmer AK
,
Nguyen NH
,
Singh S
,
Casteele NVande
et al.
. 2021.
Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 19(3):511-518.e6.
C
Cohen-Mekelburg S
,
Tafesh Z
,
Coburn E
,
Weg R
,
Malik N
,
Webb C
,
Hammad H
,
Scherl E
,
Bosworth BP
. 2018.
Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.
.
Dig Dis Sci. 63(9):2439-2444.
D
Dulai PS
,
Battat R
,
Barsky M
,
Nguyen NH
,
Ma C
,
Narula N
,
Mosli M
,
Casteele NVande
,
Boland BS
,
Prokop L
et al.
. 2020.
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
.
Am J Gastroenterol. 115(6):885-894.
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
J
Jacob V
,
Crawford C
,
Cohen-Mekelburg S
,
Viladomiu M
,
Putzel GG
,
Schneider Y
,
Chabouni F
,
OʼNeil S
,
Bosworth B
,
Woo V
et al.
. 2017.
Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.
.
Inflamm Bowel Dis. 23(6):903-911.
M
Murphy SJ
,
Wang L
,
Anderson LA
,
Steinlauf A
,
Present DH
,
Mechanick JI
. 2009.
Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: a proposed method.
.
Aliment Pharmacol Ther. 30(10):1078-86.
N
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
P
Panaccione R
,
Danese S
,
Sandborn WJ
,
O'Brien CD
,
Zhou Y
,
Zhang H
,
Adedokun OJ
,
Tikhonov I
,
Targan S
,
Abreu MT
et al.
. 2020.
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
.
Aliment Pharmacol Ther. 52(11-12):1658-1675.
S
Sandborn WJ
,
Feagan BG
,
Fedorak RN
,
Scherl E
,
Fleisher MR
,
Katz S
,
Johanns J
,
Blank M
,
Rutgeerts P
. 2008.
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
.
Gastroenterology. 135(4):1130-41.
Steinlauf AF
,
Garcia-Tsao G
,
Zakko MF
,
Dickey K
,
Gupta T
,
Groszmann RJ
. 1999.
Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements.
.
Hepatology. 29(4):1070-3.
Steinlauf AF
,
Marion JF
,
Sacchar D
,
Sandler AL
,
Greenstein AJ
,
Harris MT
. 2011.
Ileouterine fistulae: possible predisposing factors to this rare complication of Crohn's disease.
.
Inflamm Bowel Dis. 17(3):872-3.
Y
Yang E
,
Panaccione N
,
Whitmire N
,
Dulai PS
,
Casteele NVande
,
Singh S
,
Boland BS
,
Collins A
,
Sandborn WJ
,
Panaccione R
et al.
. 2020.
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
.
Aliment Pharmacol Ther. 51(11):1031-1038.